Mereo BioPharma (MREO) Assets (2017 - 2026)

Mereo BioPharma (MREO) has reported Assets for 8 consecutive years, with $40.6 million the latest figure, recorded in Q1 2026.

• Quarterly Assets fell 40.56% year-over-year to $40.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.6 million (down 40.56% YoY) and the FY2025 annual result came in at $45.9 million, down 39.89% from the prior year.
• Assets eased to $40.6 million in Q1 2026 per MREO's latest filing, from $45.9 million in the prior quarter.
• Over the last five years, Assets for MREO reached as high as $96.1 million in Q2 2024 and fell as low as $40.6 million in Q1 2026.
• A 4-year average of $65.5 million and a median of $64.6 million in 2023 frame the typical range for Assets.
• Annual changes were most pronounced in 2025 — Assets rose 22.14% — and 2026, when it slumped 40.56%.
• Year by year, Assets stood at $66.5 million in 2023, then increased by 14.87% to $76.4 million in 2024, then slumped by 39.89% to $45.9 million in 2025, then declined by 11.55% to $40.6 million in 2026.
• According to Business Quant data, Assets over the past three periods registered $40.6 million, $45.9 million, and $53.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.